TREATMENT

TREATMENT

Spinal stenosis – Diagnosis and treatment

Diagnosis

To diagnose spinal stenosis, your doctor may ask you about signs and symptoms, discuss your medical history, and conduct a physical examination. He or she may order several imaging tests to help pinpoint the cause of your signs and symptoms.

Imaging tests

These tests may include:

  • X-rays. An X-ray of your back can reveal bony changes, such as bone spurs that may be narrowing the space within the spinal canal. Each X-ray involves a small exposure to radiation.
  • Magnetic resonance imaging (MRI). An MRI uses a powerful magnet and radio waves to produce cross-sectional images of your spine. The test can detect damage to your disks and ligaments, as well as the presence of tumors. Most important, it can show where the nerves in the spinal cord are being pressured.
  • CT or CT myelogram. If you can’t have an MRI, your doctor may recommend computerized tomography (CT), a
Read More Read More
TREATMENT

Ivory Coast PM in ‘good shape’ after return from France


Ivory Coast Prime Minister Patrick Achi.

Cyrille Bah/Anadolu Agency via Getty Images

Ivory Coast Prime Minister Patrick Achi said he was in “good shape” after returning home to Abidjan on Friday, following reported medical treatment in France.

Achi, 65, spent five days in France undergoing tests for “severe fatigue” suffered since his appointment in March, two sources told Reuters.

A close confidant of President Alassane Ouattara, Achi was named prime minister following the death of the West African cocoa producer’s second premier in less than eight months.

He replaced Hamed Bakayoko, who died of cancer at 56. Bakayoko had replaced Amadou Gon Coulibaly, who died following cardiac issues last July.

State television showed Achi deplaning and being greeted by ministers on the tarmac in Ivory Coast’s commercial capital Abidjan on Friday night.

Achi said:

I feel very good. I came back in good shape to go back to work.

Read More Read More
TREATMENT

Congenital Diaphragmatic Hernia (CDH)

What is CDH?

Illustration of CDH with lung compression

The wide, flat muscle that separates the chest and abdominal cavities is called the diaphragm. The diaphragm forms when a fetus is at 8 weeks’ gestation. When it does not form completely, a defect, called a congenital diaphragmatic hernia (CDH), is created. This is a hole in the muscle between the chest and the abdomen.

The majority of CDHs occur on the left side. The hole allows the contents of the abdomen (stomach, intestine, liver, spleen, and kidneys) to go up into the fetal chest. The herniation of these abdominal organs into the chest occupies that space and prevents the lungs from growing to normal size. The growth of both lungs can be affected. The result of this is called pulmonary hypoplasia.

While in the uterus, a fetus does not need its lungs to breathe, because the placenta performs this function. However, if the lungs are too

Read More Read More
TREATMENT

Can I get the COVID-19 vaccine if I am undocumented?

Yes. Everyone 12 or older who lives, works, or studies in New Jersey is now eligible for the COVID-19 vaccine.

If you are uninsured, you can still receive a vaccine. The vaccine is free – there is no cost to you. Learn more about insurance coverage for COVID-19 vaccines here. If you are insured, you are encouraged to bring your insurance information so that the site can get reimbursed at no cost to you.

Documentation is not required to be vaccinated. Vaccine sites may request documentation, but you are not required to have it to receive the vaccine and you cannot be denied access to the vaccine for not having ID. Sites will NOT ask for proof of immigration status.

U.S. Immigration and Customs Enforcement (ICE) and U.S. Customs and Border Protection will not conduct enforcement operations at or near vaccine distribution sites or clinics.

Any data collected for the

Read More Read More
TREATMENT

Twin to Twin Transfusion Syndrome (TTTS)

What is Twin to Twin Transfusion Syndrome (TTTS)?

Because there is no barrier separating the two fetuses from each other, there are almost always blood vessel connections in the placenta shared by two fetuses in monochorionic twin (MC) pregnancies. As a result of these connections, in about 10-15% of monochorionic twins (sharing one placenta) an imbalance in the circulations of the fetuses can develop. In these instances, there may be significant transfer of blood from one twin (the so-called “donor”) to the other twin (the so-called “recipient”), resulting in twin-to-twin transfusion syndrome (TTTS).

illustration of normal monochorionic twins - ©chrisgralapp.com

Twin-to-Twin Transfusion Syndrome (TTTS) is a serious, progressive disorder. The twins do not have malformations, but one transfuses the other through abnormal or imbalanced blood vessel connections in the shared placenta. More specifically, an artery branches off from the donor twin’s umbilical cord, entering the placenta in order to obtain oxygen and nutrients for the blood from

Read More Read More
TREATMENT

ACLU asks judge to block Arkansas trans youth treatment ban | PA Power and Policy

LITTLE ROCK, Ark. (AP) — The American Civil Liberties Union on Tuesday asked a federal judge to prevent Arkansas from enforcing its ban on gender confirming treatments for transgender youth while a lawsuit challenging the prohibition proceeds.

The ACLU requested a preliminary injunction against the new law, which is set to take effect on July 28. It will prohibit doctors from providing gender confirming hormone treatment, puberty blockers or surgery to anyone under 18 years old, or from referring them to other providers for the treatment.

The ACLU filed a lawsuit challenging the ban last month on behalf of four transgender youth and their families, as well as two doctors who provide the treatments.

The ban is forcing some families of transgender youth to move out of state to continue their children’s treatments, if they can afford to do so, the filing contends.

“The threat of harm to plaintiffs is

Read More Read More
TREATMENT

Bahrain approves emergency use for REGN-COV2 for COVID-19 treatment

Saudi Gazette report

MANAMA — Bahrain’s National Health Regulatory Authority (NHRA) has approved REGN-COV2 for emergency use, a new drug by Regeneron in collaboration with F. Hoffmann-La Roche, for the treatment of mild to moderate COVID-19 cases, the Bahrain News Agency reported on Wednesday.

REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are drugs called “monoclonal antibodies,” that are designed to block viral attachment and entry into human cells to neutralize the virus.

REGN-COV2 also received emergency use approval from the US FDA to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents of 12 years of age and older, who weigh at least 88 pounds (40 kg), and for those who are at high risk for developing severe COVID-19 symptoms or of hospitalization.

REGN-COV2 also received a positive review from the European Medicines Agency after their analysis of the quality, safety, and efficacy aspects of

Read More Read More
TREATMENT

Causes, Symptoms, Diagnosis, Treatment, and Complications

What Is Pleurisy?

Pleurisy is a type of chest pain. It affects a part of your body called the pleura.

The pleura is a thin layer of tissue that wraps your lungs. They fit snugly within your chest, which is lined with another thin layer of pleura.

These layers keep your bare lungs from rubbing against the wall of your chest cavity every time you breathe in. There’s a bit of fluid within the narrow space between the two layers of pleura to keep everything moving smoothly.

When you’re healthy, you never notice your pleura at work. But if your pleura has a problem, you’ll feel it.

When the pleurae are swollen and inflamed, they rub against each other in a very painful way each time your lungs expand. When you inhale deeply, cough, sneeze, or laugh, you’ll probably feel a sharp, stabbing pain in the area that’s affected.

Most

Read More Read More
TREATMENT

KSOM study reveals potential new treatment target in the fight against COVID-19

Images of cells showing close proximity (yellow) of GRP78 (green) with Spike protein of SARS-Cov-2 (red) (left panels) and ACE2 (red) (right panels). Image provided by lead author Anthony Carlos, PhD.

The swift development of vaccines has provided a vital tool to combat the spread of the deadly SARS-CoV-2 virus, but challenges to reaching herd immunity posed by the rise of new mutations and the inability of immunosuppressed people to develop an effective immune response following vaccination point to a need for additional solutions to maximize protection.

A new study by Keck School of Medicine (KSOM) researchers published in the Journal of Biological Chemistry reveals how therapies targeting a molecular chaperone called GRP78 might offer additional protection against COVID-19 and other coronaviruses that emerge in the future.

Chaperones like GRP78 are molecules that help regulate the correct folding of proteins, especially when a cell is under stress. But in some

Read More Read More
TREATMENT

Oxford University explores anti-parasitic drug ivermectin as Covid-19 treatment | India News

NEW DELHI: The University of Oxford said on Wednesday it was testing anti-parasitic drug ivermectin as a possible treatment for Covid-19, as part of a British government-backed study that aims to aid recoveries in non-hospital settings.
Ivermectin resulted in a reduction of virus replication in laboratory studies, the university said, adding that a small pilot showed giving the drug early could reduce viral load and the duration of symptoms in some patients with mild Covid-19.
Dubbed PRINCIPLE, the British study in January showed that antibiotics azithromycin and doxycycline were generally ineffective against early-stage Covid-19.
While the World Health Organization, and European and US regulators have recommended against using ivermectin in Covid-19 patients, it is being used to treat the illness in some countries, including India.
“By including ivermectin in a large-scale trial like PRINCIPLE, we hope to generate robust evidence to determine how effective the treatment is against Covid-19, and
Read More Read More